TrialCancer communications (London, England)2024

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS).

Shun Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.